VASCULAR SURGERY
Complex Dialysis Access
Clinical studies and continued research in the area of complex dialysis access is a mainstay for the vascular surgery division . In fiscal year 2018 , vascular surgeons on the medical staff realized increasing volumes in referrals from throughout Texas and the greater Southwest region for complex dialysis access procedures .
With the support of an experienced and certified ultrasonography team for diagnostic support , vascular surgeons provide a wide array of surgical interventions . Last year , the team continued efforts to support the National Kidney Foundation ’ s “ Fistula First ” initiative . Surgeons are proud to be a part of the national goal of providing fistulas for the End-Stage Renal Disease patient population and in line with the goals of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative ( NKF NDOQI ) ™ .
ENDOVASCULAR TREATMENT : MINIMALLY INVASIVE SURGERY
During the past fiscal year , vascular surgeons remained on the forefront of the Super HeRO , HeRO and Ally related dialysis access devices . Research associated with the devices occurred within Baylor Scott & White Heart and Vascular Hospital - Dallas operating suites . Providing an option for patients who have been told that they do not have any further options , there is now a device that offers an option for continued dialysis access for end-stage renal disease . Vascular surgeons on the medical staff on the Dallas campus will continue to work closely with a multidisciplinary team on this evolving procedure . Patient outcomes are monitored closely and the study oversight that continued in fiscal year 2017 and fiscal year 2018 remains in place .
CLINICAL STUDY : HUMANITY TRIAL
* Image courtesy of Merit Medical
Working closely with Humacyte , a biotechnology and regenerative medicine company , vascular surgeons on the medical staff at Baylor Scott & White Heart and Vascular Hospital – Dallas have continued involvement with an investigational human acellular vessel ( HAV ) Phase III clinical study as a conduit for hemodialysis in patients with end-stage renal disease and not candidates for a fistula . As one of the several national and international trial sites , Baylor Dallas ’ HUMANITY trial is one of the largest studies of any bioengineered vascular tissues to date . According to study information , HUMACYL may offer a potentially safe and effective alternative for vascular access in hemodialysis treatment . The Dallas site ’ s primary investigator is Stephen Hohmann , MD .
45